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Abstract
The study of the cellular and molecular mechanisms underlying the consolidation and reconsolidation of traumatic fear
memories has progressed rapidly in recent years, yet few compounds have emerged that are readily useful in a clinical
setting for the treatment of anxiety disorders such as post-traumatic stress disorder (PTSD). Here, we use a combination of
biochemical, behavioral, and neurophysiological methods to systematically investigate the ability of garcinol, a naturally-
occurring histone acetyltransferase (HAT) inhibitor derived from the rind of the fruit of the Kokum tree (Garcina indica), to
disrupt the consolidation and reconsolidation of Pavlovian fear conditioning, a widely studied rodent model of PTSD. We
show that local infusion of garcinol into the rat lateral amygdala (LA) impairs the training and retrieval-related acetylation of
histone H3 in the LA. Further, we show that either intra-LA or systemic administration of garcinol within a narrow window
after either fear conditioning or fear memory retrieval significantly impairs the consolidation and reconsolidation of a
Pavlovian fear memory and associated neural plasticity in the LA. Our findings suggest that a naturally-occurring compound
derived from the diet that regulates chromatin function may be useful in the treatment of newly acquired or recently
reactivated traumatic memories.
Citation: Maddox SA, Watts CS, Doye`re V, Schafe GE (2013) A Naturally-Occurring Histone Acetyltransferase Inhibitor Derived from Garcinia indica Impairs Newly
Acquired and Reactivated Fear Memories. PLoS ONE 8(1): e54463. doi:10.1371/journal.pone.0054463
Editor: Lisa Carlson Lyons, Florida State University, United States of America
Received October 10, 2012; Accepted December 11, 2012; Published January 21, 2013
Copyright:  2013 Maddox et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by National Institutes of Health Grant MH 073949 (to G.E.S.) and by Yale University. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: glenn.schafe@yale.edu
Introduction
Newly acquired memories are thought to be inherently
unstable, acquiring stability over time as they are ‘consolidated’
into long-term representations in the brain [1]. Later memory
retrieval is known to trigger a new phase of instability for a brief
window of time during which the memory may be updated (e.g.
strengthened or weakened) prior to being re-stabilized in a process
known as ‘reconsolidation’ [2,3]. This window of lability for both
consolidation and reconsolidation has attracted considerable
experimental attention, fueled in part by the promise of
discovering novel therapeutic and/or pharmacological approaches
for the treatment of psychiatric disorders ranging from post-
traumatic stress disorder (PTSD) to drug addiction that are
characterized by unusually strong and persistent memories [4,5].
The study of the neural and molecular mechanisms underlying
the consolidation and reconsolidation of Pavlovian fear condition-
ing, an animal model of PTSD, has progressed rapidly in recent
years [5–10]. With notable exceptions [7], findings have collec-
tively suggested that fear memory consolidation and reconsolida-
tion share many of their core molecular features in common,
including NMDA-receptor driven activation of protein kinase
signaling cascades [11–16], the involvement of transcription
factors [17,18], de novo mRNA and protein synthesis [19–22],
and the involvement of immediate early genes [23–27]. However,
the majority of the pharmacological agents that have been used to
disrupt fear memory consolidation and/or reconsolidation in
animal models, including mRNA and protein synthesis inhibitors
[19,20,28,29], antisense oligonucleotides [23–25], and viral
vectors [17,27,30], are not readily applicable in humans due to
potential issues with drug delivery and toxicity. The b-adrenergic
antagonist propranolol is an exception to this rule and has received
considerable experimental attention for its ability to impair both
newly formed and reactivated fear memories in preclinical studies
[31–33]. However, propranolol has not been shown to be effective
in every study [34], and its effectiveness in treating symptoms of
PTSD in humans has yielded mixed results [35–39]. It is thus of
considerable interest to investigate the efficacy of other compounds
that are similarly suitable for human consumption which may be
used either alone or in combination with existing methods during
the lability window to attenuate fearful or traumatic memories.
In recent years, interest has turned toward the examination of a
relatively new class of pharmacological agents that target so-called
‘epigenetic’ processes in the treatment of neuropsychiatric
disorders [40–42]. Epigenetic modifications, including alterations
in chromatin structure and DNA methylation, have been widely
implicated in memory and cognition [41,43–45]. Chromatin,
which consists of DNA packaged tightly around a core of eight
histones, is known to be dynamically regulated by acetylation of
histones via histone acetyltransferases (HATs). Acetylation causes
chromatin structure to relax, leading to enhanced transcription, a
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process that is readily reversible via a second family of chromatin
modifying enzymes known as histone deacetylases (HDACs) [46–
48]. In a clinical context, studies have suggested that enhancing
histone acetylation through HDAC inhibition can rescue the
memory deficits associated with cognitive disorders ranging from
certain forms of intellectual disabilities to Alzheimer’s disease [49–
53]. However, while enhancing histone acetylation has shown
promise for treating neuropsychiatric disorders characterized by
memory impairment, traumatic fear memories are an example of
a memory-related psychiatric disorder in which it is desirable to
impair, rather than enhance, the memory trace.
In the present study, we explore the potential efficacy of a
relatively novel and naturally-occurring HAT inhibitor known as
garcinol [54,55], derived from the rind of the fruit of the Kokum
tree (Garcinia indica), in the treatment of newly formed and
reactivated fear memories. We show that garcinol impairs histone
acetylation in the lateral nucleus of the amygdala (LA) associated
with fear conditioning and retrieval of a fear memory. Further, we
show that intra-LA or systemic administration of garcinol within a
narrow time window after fear conditioning or fear memory
retrieval impairs the consolidation and reconsolidation of a fear
memory in a time-limited and retrieval-specific manner. Collec-
tively, our findings suggest the intriguing possibility that a
naturally-occurring compound derived from the diet may be
useful in the treatment of newly acquired or recently reactivated
traumatic memories.
Results
Local infusion of garcinol into the amygdala shortly after
fear conditioning impairs the consolidation of a fear
memory
In our first series of experiments, we asked whether local
infusion of garcinol into the LA, the presumed locus of fear
memory acquisition and storage [8,10,56,57], can impair the
consolidation of a fear memory. In our first experiment, rats were
fear conditioned with three pairings of a tone (conditioned
stimulus; CS) with footshock (unconditioned stimulus; US)
followed 1 hr later by intra-LA infusion of either vehicle (0.5 ml/
side) or garcinol (500 ng/side; 0.5 ml). A portion of the rats was
Figure 1. Intra-LA infusions of garcinol impair training-related acetylation of histone H3 and fear memory consolidation. (a)
Schematic of the behavioral protocol. Rats were fear conditioned with three tone-shock pairings followed 1 hr later by intra-LA infusion of either
vehicle (n = 7) or garcinol (500 ng/side; n= 7) and were sacrificed 30 min later. A third group did not receive conditioning and was infused with
vehicle prior to sacrifice (n = 7). Separate groups of rats were fear conditioned with three tone-shock pairings followed 1 hr later by intra-LA infusion
of either vehicle (n = 9) or garcinol (500 ng/side; n = 8) and tested for STM and LTM 3 and 21 hrs later, respectively. (b) Western blot analysis of
acetylated and total (non-acetylated) histone H3 from LA homogenates from naı¨ve (N)-Vehicle, fear conditioned (FC)-Vehicle and FC-Garcinol groups.
* p,0.05 relative to FC-vehicle and N-Vehicle groups. Representative Western blots are depicted in the inset. (c) Mean (6 SEM) percent freezing
during the STM and LTM tests in vehicle and garcinol-infused groups. A third group is depicted that received infusion of either vehicle (n = 8) or
garcinol (n= 6) 6 hrs following fear conditioning (‘delayed infusion’) followed by a LTM test 21 hrs later. (d) Cannula placements for rats infused with
either vehicle (black circles) or garcinol (gray circles). *p,0.05 relative to vehicle-infused controls.
doi:10.1371/journal.pone.0054463.g001
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Figure 2. Garcinol impairs retrieval-related acetylation of histone H3 in the LA and fear memory reconsolidation. (a) Schematic of the
behavioral protocol. Rats were fear conditioned with three tone-shock pairings. Twenty four hrs following training rats were given a memory
reactivation session consisting of a single tone CS presentation followed 1 hr later by intra-LA infusions of vehicle (n= 8) or garcinol (500 ng/side;
n = 7). All rats were sacrificed 30 min following infusion. A third group did not receive conditioning or retrieval testing and was infused with vehicle
prior to sacrifice (n= 7). Separate groups of rats were fear conditioned followed 24 hr later by a memory reactivation session consisting of a single
tone CS presentation followed 1 hr later by intra-LA infusion of vehicle (n= 9) or garcinol (500 ng/side; n = 8). Two additional groups of rats were
given a ‘no-reactivation’ session followed by infusion of vehicle (n = 7) or garcinol (500 ng/side; n = 5). All rats were then tested for PR-STM and PR-
LTM 3 and 21 hrs later, respectively. (b) Cannula placements for rats infused with either vehicle (black circles) or garcinol (gray circles). (c) Memory
retrieval data for the Reactivated (R)-Garcinol and R-Vehicle groups used in the Western blotting experiments. *p,0.05 relative to the pre-CS period.
(d) Western blot analysis of acetylated and total histone H3 from LA homogenates taken from Naı¨ve (N)-vehicle, R-Vehicle and R-Garcinol groups.
* p,0.05 relative to R-Vehicle and N-Vehicle groups. Representative Western blots are depicted in the inset. (e) Memory retrieval data for the
Reactivated (R)-Garcinol and R-Vehicle groups in the behavioral experiments. *p,0.05 relative to the pre-CS period. (f) Mean (6 SEM) percent freezing
during the PR-STM and PR-LTM tests in R-Vehicle and R-Garcinol groups. A third group is depicted that received infusion of either vehicle (n = 9) or
garcinol (n = 6) 6 hrs following retrieval (‘delayed infusion’) followed by a PR-LTM test 21 hrs later. *p,0.05 relative to vehicle-infused controls. (g)
Memory retrieval data for the Non-reactivated (NR)-Garcinol and NR-Vehicle groups. (h) Mean (6 SEM) percent freezing during the ‘PR’-STM and ‘PR’-
LTM tests in NR-Vehicle and NR-Garcinol groups.
doi:10.1371/journal.pone.0054463.g002
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sacrificed 30 min later (90 min after training [58]) to examine the
effect of garcinol on the training-related acetylation of histone H3
in the LA (Figure 1a). The remaining rats received tests of short-
term memory (STM) and long-term memory (LTM) in a distinct
chamber at 3 hr and 21 hr following infusion, respectively
(Figure 1a).
Western blotting revealed that infusion of garcinol following
auditory fear conditioning significantly impaired the training-
related acetylation of histone H3 in the LA [F(2,18) = 15.3,
p,0.05; Figure 1b]. Duncan’s post-hoc t-tests revealed that the
fear conditioned (FC)-Garcinol group exhibited significantly
lower levels of H3 acetylation relative to the FC-Vehicle group
(p,0.05) that did not differ significantly from naı¨ve (N)-Vehicle
controls (p.0.05). Importantly, no differences were observed in
total (non-acetylated) levels of histone H3 [F(2,18) = 0.14;
Figure 1b] or in the loading protein GAPDH [F(2,18) = 0.33;
data not shown].
In our behavioral experiments, vehicle and garcinol-infused rats
exhibited equivalent levels freezing during the STM test
[t(15) = 0.38; Figure 1c], indicating that garcinol has no effect on
STM. However, the following day garcinol-treated rats exhibited
impaired LTM relative to the vehicle-infused group [t(15) = 14.3,
p,0.01; Figure 1c]. Further, we found that the effect of garcinol
on fear memory consolidation is temporally constrained; when rats
were given intra-LA infusion of garcinol 6 hr following training
there was no effect on LTM [t(12) = 1.54; Figure 1c]. Thus, intra-
LA infusion of garcinol within a narrow window (1 hr) following
Pavlovian fear conditioning can significantly impair the training
related acetylation of histone H3 in the LA and the consolidation
of a fear memory.
Local infusion of garcinol into the amygdala shortly after
fear memory retrieval impairs the reconsolidation of a
fear memory
In our second series of experiments, we asked whether local
infusion of garcinol into the LA shortly after fear memory retrieval
can impair the reconsolidation of a fear memory. Rats were fear
conditioned as before followed 24 h later by a fear memory
retrieval (or ‘reactivation’) session consisting of a single tone CS
presentation. One hour following fear memory reactivation, rats
received intra-LA infusion of either vehicle (0.5 ml/side) or
garcinol (500 ng/side; 0.5 ml). A portion of the rats was sacrificed
30 min later (90 min after retrieval [59]) to examine the effect of
garcinol on the retrieval-related acetylation of histone H3 in the
LA (Figure 2a). The remaining rats received tests of post-
reactivation short-term memory (PR-STM) and post-reactivation
long-term memory (PR-LTM) at 3 hr and 21 hr after infusion,
respectively (Figure 2a).
In our Western blotting experiments, both vehicle- and
garcinol-infused rats exhibited significant and equivalent memory
recall during the reactivation session; the ANOVA (group by trial)
revealed a significant main effect of trial [pre-CS vs. CS;
F(1,13) = 555.01, p,0.05], but no significant main effect of group
[F(1,13) = 0.09; Figure 2c]. Further, infusion of garcinol following
fear memory reactivation resulted in a significant reduction in the
retrieval-related acetylation of histone H3 in the LA
[F(2,19) = 4.376, p,0.05; Figure 2d]. Duncan’s post-hoc t-tests
revealed that the reactivated (R)-Garcinol group exhibited
significantly lower levels of H3 acetylation relative to the R-
Vehicle group (p,0.05) that did not differ significantly from the
naı¨ve (N)-Vehicle group (p.0.05). Moreover, no differences were
observed in total protein levels of histone H3 [F(2,19) = 0.002;
Figure 2d] or in the loading protein GAPDH [F(2,19) = 0.84; data
not shown].
In our behavioral experiments, both vehicle- and garcinol-
treated rats exhibited significant and equivalent memory recall
during the reactivation session; the ANOVA (group by trial)
revealed a significant main effect of trial [pre-CS vs. CS;
Figure 3. The effect of garcinol on fear memory reconsolida-
tion is not sensitive to spontaneous recovery, reinstatement,
or to a shift in testing context. (a) Schematic of the behavioral
protocol (see text for details). (b) Memory retrieval data for rats given
intra-LA infusion of vehicle (n = 6) or garcinol (n = 6). *p,0.05 relative to
the pre-CS period. (c) Mean (6 SEM) percent freezing during the PR-
STM and PR-LTM tests in vehicle and garcinol-infused rats. *p,0.05
relative to vehicle-infused controls. (d) Mean (6 SEM) percent freezing
during the spontaneous recovery, reinstatement, and context shift
tests. (e) Cannula placements for rats infused with either vehicle (black
circles) or garcinol (gray circles). *p,0.05 relative to vehicle-infused
controls.
doi:10.1371/journal.pone.0054463.g003
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F(1,15) = 2613.88, p,0.01], but no significant main effect of group
[F(1,15) = 0.01; Figure 2e]. Further, both groups exhibited
equivalent levels of freezing during the PR-STM test
[t(15) = 1.59; Figure 2f], indicating that garcinol has no effect on
the retention of a fear memory when the animals are tested
shortly after memory reactivation and infusion. However, the
following day garcinol-treated rats exhibited impaired PR-LTM
compared to the vehicle group [t(15) = 9.81, p,0.01; Figure 2f].
Further, similar to that observed in our consolidation experi-
ments, we found that the effect of garcinol on fear memory
reconsolidation is temporally constrained; when rats were given
intra-LA infusion of garcinol 6 hrs following memory reactivation
there was no effect on PR-LTM [t(13) = 0.40 Figure 2f]. Thus,
intra-LA infusion of garcinol within a narrow window (1 hr)
following fear memory retrieval can significantly impair retrieval-
related acetylation of histone H3 in the LA and the reconsolida-
tion of a fear memory.
Importantly, in a separate experiment we observed that the
reconsolidation disruption produced by garcinol is specific to a
reactivated memory. Rats were fear conditioned as before,
followed 24 h later by a ‘no-reactivation’ session in which they
were placed in the testing context without a tone presentation.
One hour following the ‘no-reactivation’ session, rats received
intra-LA infusion of either vehicle (0.5 ml) or garcinol (500 ng/
side; 0.5 ml) followed 3 and 21 h later by tests of ‘PR’-STM and
‘PR’-LTM (Figure 2a). Analysis of the reactivation session data
revealed that both groups showed equivalently low levels of
freezing during the ‘pre-CS’ period and during the 30 sec period
when the tone would have been presented during the reactiva-
tion session (Figure 2g). An ANOVA (group by trial) revealed no
significant effect of group [F(1,10) = 0.57] or trial [F(1,10) = 0.83].
Similarly, both vehicle and garcinol-treated rats exhibited
equivalently high levels of freezing during the ‘PR’-STM test
[t(10) = 0.37; Figure 2h] and the ‘PR’-LTM test [t(10) = 0.53;
Figure 2h], indicating that garcinol is only effective at impairing
a fear memory in a reconsolidation paradigm if administered
around the time of active memory recall.
Fear memories that fail to reconsolidate following
treatment with garcinol are impaired in an enduring
manner
Our experiments thus far collectively suggest that local
infusion of garcinol into the LA impairs reconsolidation of an
auditory fear memory in a time-limited and retrieval-specific
manner. Previous studies have shown that amygdala-dependent
fear memories that are lost due to interference with the
reconsolidation process are lost in an enduring manner; they
are not sensitive to spontaneous recovery, reinstatement, or
renewal in a new testing context [25,32,33,59,60]. Here, we
asked whether the reconsolidation deficit induced by garcinol is
similarly insensitive to spontaneous recovery, reinstatement, or to
a shift in the testing context. Rats were fear conditioned as
before followed 24 h later by a reactivation trial in a distinct
context (Chamber B). One hour later, rats were given intra-LA
infusion of either vehicle (0.5 ml/side) or garcinol (500 ng/
side;0.5 ml) followed 3 and 21 hrs later by tests of PR-STM and
Figure 4. Intra-LA infusion of garcinol impairs the reconsolidation of a ‘well-consolidated’ fear memory. (a) Rats were fear conditioned
with three tone-shock pairings. Two weeks following training rats were given a memory reactivation session consisting of a single tone CS
presentation followed 1 hr later by intra-LA infusion of vehicle (n = 5) or garcinol (500 ng/side; n= 6). (b) Memory retrieval data for the vehicle and
garcinol-infused groups. *p,0.05 relative to the pre-CS period. (c) Mean (6 SEM) percent freezing during the PR-STM and PR-LTM tests in vehicle and
garcinol-infused rats. (d) Cannula placements for rats infused with either vehicle (black circles) or garcinol (gray circles). *p,0.05 relative to vehicle-
infused controls.
doi:10.1371/journal.pone.0054463.g004
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PR-LTM in Chamber B. One week later, rats were re-tested for
spontaneous recovery of the fear memory in Chamber B. The
next day, rats underwent a fear reinstatement session in a novel
context (Chamber C) consisting of exposure to three unsignaled
footshocks [60] followed 24 h later by a third test of fear memory
in Chamber B (Reinstatement Test). Finally, rats were placed in
another novel context (Chamber D) and tested with three tone
CS presentations to examine whether fear to the tone re-emerges
Figure 5. Intra-LA infusion of garcinol impairs fear memory consolidation and the consolidation of training-related neural plasticity
in the LA. (a) Rats were given two baseline AEFP recording sessions on separate days followed by fear conditioning with three tone-pip-shock
pairings followed 1 hr later by intra-LA infusion of either vehicle (n = 8) or garcinol (500 ng/side; n = 7). Rats in each group were then tested for STM
and LTM 3 and 21 hrs later while AEFPs were recorded from the LA. (b) Mean (6 SEM) percent freezing during the STM and LTM tests in vehicle and
garcinol-infused groups. (c) Mean (6 SEM) percent of change in AEFP amplitude during the STM and LTM tests in vehicle and garcinol-infused rats,
relative to baseline. *p,0.05 relative to vehicle-infused controls. (d) Representative AEFPs recorded from the LA for each group during baseline (light
gray trace), STM and LTM sessions (darker traces). Scale bar = 10 mV, 5 ms. (e) Electrode placements for rats infused with either vehicle (black circles)
or garcinol (gray circles).
doi:10.1371/journal.pone.0054463.g005
Garcinol and Fear Memory
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e54463
when the animals are tested outside of original reconsolidation
testing context (Context Shift) (Figure 3a).
During the original reactivation session, both groups showed
equivalently high levels of memory retrieval (Figure 3b); the
ANOVA (group by trial) revealed a significant main effect of trial
[pre-CS vs. CS; F(1,10) = 2790.12, p,0.01] but not of group
[F(1,10) = 0.04]. Further, consistent with our previous experiments,
garcinol-treated rats showed intact memory during the PR-STM
test [t(10) = 0.20], but impaired memory retention during the PR-
LTM test [t(10) = 5.34, p,0.01; Figure 3c]. Importantly, during the
test of spontaneous recovery 1 week later, garcinol-treated rats
continued to exhibit memory impairment while the vehicle control
group exhibited high levels of retention [t(10) = 11.33, p,0.01;
Figure 3d]. During the reinstatement session administered on the
Figure 6. Intra-LA infusion of garcinol impairs fear memory reconsolidation and memory-related neural plasticity in the LA. (a) Rats
were given two baseline AEFP recording sessions on separate days followed by fear conditioning with three tone-pip-shock pairings. Twenty four hrs
following training rats were given a memory reactivation session consisting of a single tone-pip CS presentation followed 1 hr later by intra-LA
infusions of vehicle (n = 5) or garcinol (500 ng/side; n = 7). Rats in each group were then tested for PR-STM and PR-LTM 3 and 21 hrs later while AEFPs
were recorded from the LA. (b) Memory retrieval data for the vehicle and garcinol-infused groups. *p,0.05 relative to the pre-CS period. (c) Mean
(6 SEM) percent freezing during the PR-STM and PR-LTM tests in vehicle and garcinol-infused groups. (d) Mean (6 SEM) percent of change in AEFP
amplitude during the PR-STM and PR-LTM tests in vehicle and garcinol-infused rats, relative to baseline. *p,0.05 relative to vehicle-infused controls.
(e) Representative AEFPs recorded from the LA for each group during baseline (light gray trace), PR-STM and PR-LTM sessions (darker traces). Scale
bar = 10 mV, 5 ms. (f) Electrode placements for rats infused with either vehicle (black circles) or garcinol (gray circles).
doi:10.1371/journal.pone.0054463.g006
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next day, both groups exhibited significant post-shock freezing in
Chamber C (data not shown). An ANOVA (group by trial)
revealed a significant main effect of trial [pre-shock vs. post-shock
period; F(3,30) = 412.4, p,0.01] but not of group [F(1,10) = 0.55],
indicating an increase in freezing relative to the pre-shock period
in both groups. When re-tested 24 hrs later for evidence of
reinstatement of fear in Chamber B, however, garcinol-treated rats
continued to exhibit memory impairment while the vehicle group
exhibited high levels of freezing [t(10) = 9.68, p,0.01; Figure 3d],
suggesting that the garcinol-induced reconsolidation deficit is not
sensitive to reinstatement following exposure to an aversive event
equivalent in strength to the original aversive experience. Finally,
during the context shift test in Chamber D, garcinol-treated rats
continued to exhibit memory impairment while the vehicle group
Figure 7. Intra-LA infusion of garcinol in the absence of fear memory retrieval has no effect on fear memory reconsolidation or
memory-related neural plasticity in the LA. (a) Rats were given two baseline AEFP recording sessions on separate days followed by fear
conditioning with three tone-pip-shock pairings. Twenty four hrs following training rats were given a ‘no-reactivation’ session followed by infusion of
vehicle (n= 7) or garcinol (500 ng/side; n = 6). Rats in each group were then tested for ‘PR’-STM and ‘PR’-LTM 3 and 21 hrs later while AEFPs were
recorded from the LA. (b) Memory retrieval data for the vehicle and garcinol-infused groups. (c) Mean (6 SEM) percent freezing during the ‘PR’-STM
and ‘PR’-LTM tests in vehicle and garcinol-infused groups. (d) Mean (6 SEM) percent of change in AEFP amplitude during the ‘PR’-STM and ‘PR’-LTM
tests in vehicle and garcinol-infused rats, relative to baseline. *p,0.05 relative to vehicle-infused controls. (e) Representative AEFPs recorded from the
LA for each group during baseline (light gray trace), ‘PR’-STM and ‘PR’-LTM sessions (darker traces). Scale bar = 10 mV, 5 ms. (f) Electrode placements
for rats infused with either vehicle (black circles) or garcinol (gray circles).
doi:10.1371/journal.pone.0054463.g007
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exhibited high levels of freezing [t(10) = 7.49, p,0.01], suggesting
that fear memories that are lost following treatment with garcinol
in a reconsolidation paradigm do not re-emerge in a different
testing context (Figure 3d).
Garcinol effectively impairs the reconsolidation of an
older fear memory
In each of our previous experiments, we reactivated the fear
memory within 24 hrs following training. We next asked whether
garcinol can impair the reconsolidation of an older, ‘well-
consolidated’ memory. Rats were fear conditioned as before
followed 2 weeks later by a memory reactivation trial and intra-LA
infusion of either vehicle (0.5 ml/side) or garcinol (500 ng/side;
0.5 ml; Figure 4a). Both groups showed equivalently high levels of
freezing during the reactivation session (Figure 4b); an ANOVA
(group by trial) revealed a significant main effect of trial [pre-CS
vs. CS; F(1,9) = 1540.99, p,0.01] but not of group [F(1,9) = 0.10].
Three hours following memory reactivation and drug infusion,
both vehicle and garcinol-infused groups displayed equivalent
levels of freezing during the PR-STM test [t(9) = 0.04; Figure 4c].
Figure 8. Systemic injection of garcinol impairs the consolidation and reconsolidation of a fear memory. (a) Schematic of the
behavioral protocol. In the consolidation experiment, rats were fear conditioned with two tone-shock pairings followed 30 min later by i.p. injection
of either garcinol (10 mg/kg; n = 8) or vehicle (n = 8). STM was examined 3 hrs later and LTM 21 hrs following injections. In the reconsolidation
experiment, rats were fear conditioned with two tone-shock pairings followed 24 hrs later by fear memory reactivation session and i.p. injection of
either garcinol (R-Garcinol; n = 9) or vehicle (R-Vehicle; n = 9). A third group received garcinol following a no-reactivation control session (NR-Garcinol;
n = 8). All rats received tests of PR-STM and PR-LTM 3 hrs and 21 hrs after injections, respectively. (b) Mean (6 SEM) percent freezing during the STM
and LTM tests in vehicle and garcinol-infused groups in the consolidation experiment. * p,0.05 relative to vehicle group. (c) Memory retrieval data
for the R-Vehicle, R-Garcinol, and NR-Garcinol groups in the reconsolidation experiment. *p,0.05 relative to the pre-CS period. (d) Mean (6 SEM)
percent freezing during the PR-STM and PR-LTM tests in R-Vehicle, R-Garcinol, and NR-Garcinol groups. *p,0.05 relative to vehicle-infused controls.
doi:10.1371/journal.pone.0054463.g008
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On the following day, however, garcinol-treated rats exhibited
impaired PR-LTM relative to the vehicle-infused controls
[t(9) = 10.69, p,0.05; Figure 4c]. Thus, even older, ‘well-consol-
idated’ memories are susceptible to reconsolidation impairment
using garcinol.
Local infusion of garcinol into the amygdala shortly after
fear conditioning impairs the consolidation of training-
related neural plasticity in the LA
We next asked whether garcinol can impair the consolidation
of training-related enhancements in tone-evoked neural activity
in the LA, a neurophysiological correlate of fear conditioning
[10,61,62]. Rats were fear conditioned with 3 pairings of a
modified tone CS with footshock (see Methods) followed 1 hr
later by intra-LA infusion of vehicle (0.5 ml/side) or garcinol
(500 ng/side; 0.5 ml). All rats then received tests of STM and
LTM 3 and 21 hr later while auditory-evoked field potentials
(AEFPs) were recorded from the LA (Figure 5a). As in our
previous experiments, we found that intra-LA infusion garcinol
had no effect on STM [t(13) = 0.77; Figure 5b] yet significantly
impaired LTM [t(13) = 14.65, p,0.01] relative to vehicle-infused
controls (Figure 5b). Similarly, analysis of the neurophysiological
data revealed that both vehicle- and garcinol-infused rats
exhibited significant enhancements in the amplitude of the
short-latency component (,12–16 ms) of the AEFP in the LA
during the STM test relative to baseline [vehicle: t(7) = 4.65,
p,0.05; garcinol: t(6) = 6.67, p,0.05] that did not differ from
each other [t(13) = 0.26; Figure 5c]. However, during the LTM
test garcinol-treated rats exhibited significantly less AEFP
amplitude change relative to vehicle-infused controls
[t(13) = 2.90, p,0.05; Figure 5c]. Thus, intra-LA infusion of
garcinol shortly following training can significantly impair, in
parallel, both the consolidation of a fear memory and the
consolidation of training-related neural plasticity in the LA.
Local infusion of garcinol into the amygdala shortly after
fear memory retrieval impairs memory-related neural
plasticity in the LA
We next examined the effect of post-retrieval administration of
garcinol on memory-related neural plasticity in the LA [63]. Rats
were fear conditioned as before followed 24 h later by a
reactivation session consisting of a single presentation of a
modified tone CS (see Methods). One hr following the
reactivation session, rats received intra-LA infusion of either
vehicle (0.5 ml/side) or garcinol (500 ng/side; 0.5 ml) followed 3
and 21 h later by tests of PR-STM and PR-LTM while AEFPs
were recorded from the LA (Figure 6a). Analysis of the
reactivation session data revealed that both vehicle- and
garcinol-infused rats exhibited significant and equivalent memory
recall during the reactivation session; the ANOVA (group by
trial) revealed a significant effect of trial [pre-CS vs. CS;
F(1,10) = 1091.79, p,0.05], but not of group [F(1,10) = 0.24;
Figure 6b]. Further, as in our previous experiments, we found
that intra-LA infusion garcinol had no effect on PR-STM
[t(10) = 0.58; Figure 6c] but significantly impaired PR-LTM
relative to vehicle-infused controls [t(10) = 7.74, p,0.01;
Figure 6c]. Analysis of the neurophysiology revealed that both
vehicle- and garcinol-infused rats exhibited significant retention
of training-related enhancements in the amplitude of the AEFP
in the LA during the PR-STM test relative to baseline [vehicle:
t(4) = 5.83, p,0.05; garcinol: t(6) = 5.29, p,0.05] that did not
differ from each other [t(10) = 0.59; Figure 6d]. However, during
the PR-LTM test garcinol-treated rats exhibited significantly less
AEFP amplitude change relative to vehicle-infused controls
[t(10) = 4.66, p,0.01; Figure 6d]. Thus, intra-LA infusion of
garcinol shortly following fear memory retrieval significantly
impairs the reconsolidation of a fear memory and, in parallel,
leads to a reversal in training-related enhancements in tone-
evoked neural activity in the LA.
Importantly, we found that the effect of post-retrieval
administration of garcinol on memory-related neural plasticity
is specific to active fear memory retrieval. Rats were fear
conditioned as before followed 24 h later by a ‘no-reactivation’
session in which they were placed in the testing chamber without
a CS presentation. One hr following the ‘no-reactivation’ session,
rats received intra-LA infusion of either vehicle (0.5 ml/side) or
garcinol (500 ng/side; 0.5 ml) followed 3 and 21 hr later by tests
of ‘PR’-STM and ‘PR’-LTM (Figure 7a). As expected, analysis of
the ‘no reactivation’ session data revealed that both groups
displayed equivalently low levels of freezing during the ‘pre-CS’
period and during the 20 sec period when the CS would have
been presented during the reactivation session (Figure 7b). An
ANOVA (group by trial) revealed no significant effect of group
[F(1,11) = 0.04] or trial [F(1,11) = 0.11]. Similarly, both vehicle and
garcinol-treated rats exhibited equivalently high levels of freezing
during the ‘PR’-STM test [t(11) = 1.01; Figure 7c] and during the
‘PR’-LTM test [t(11) = 0.27; Figure 7c]. Analysis of the neuro-
physiology revealed that both vehicle and garcinol-infused rats
exhibited significant enhancements in AEFP amplitude relative to
baseline during the ‘PR’-STM test [vehicle: t(6) = 12.20, p,0.05;
garcinol: t(5) = 4.84, p,0.05] that did not differ from each other
[‘PR’-STM: t(11) = 0.33; Figure 7d]. Further, we observed no
differences in AEFP amplitude between the two groups during
the PR-LTM test [t(11) = 0.08; Figure 7d]. Thus, garcinol is only
effective at impairing memory-associated neural plasticity when it
is administered around the time of active memory recall.
Systemic administration of garcinol shortly after fear
conditioning or fear memory retrieval impairs the
consolidation and reconsolidation of a fear memory
Our experiments thus far suggest that local infusion of garcinol
into the LA can significantly impair newly formed or reactivated
fear memories and associated neural plasticity in the LA. In a
clinical setting, however, it is desirable to administer drugs
systemically. Accordingly, in our final series of experiments, we
asked whether systemic administration of garcinol can impair
both fear memory consolidation and reconsolidation.
In our first experiment, rats were fear conditioned with two
tone-shock pairings. Thirty min following training, rats received
i.p. injection of either vehicle or garcinol (10 mg/kg) followed 3
and 21 hr later by tests of STM and LTM, respectively
(Figure 8a). Both vehicle and garcinol-treated rats exhibited
equivalent levels of freezing during the STM test [t(14) = 1.77,
p.0.05; Figure 8b], indicating, as we observed in our previous
experiments, that garcinol does not impair STM. However, the
following day garcinol-treated rats exhibited impaired LTM
relative to the vehicle-injected group [t(14) = 5.86, p,0.01;
Figure 8b].
In our reconsolidation experiment, rats were fear conditioned as
before followed 24 h later by either a fear memory reactivation
session or a ‘no-reactivation’ session administered in a distinct
context. Thirty min following reactivation, rats received systemic
injection of either vehicle or garcinol (10 mg/kg) to comprise three
groups: Reactivated (R)-Vehicle, R-Garcinol, and Non-Reactivat-
ed (NR)-Garcinol. All three groups were then tested for PR-STM
and PR-LTM at 3 and 21 hrs following injection, respectively
(Figure 8a). During the reactivation session, both reactivated
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groups showed significant and equivalent memory recall, while the
non-reactivated control group did not (Figure 8c). An ANOVA
(group by trial) revealed significant main effects of group
[F(2,23) = 110.52, p,0.01], trial [pre-CS vs. CS; F(1,23) = 938.95,
p,0.01] and the group by trial interaction [F(2,23) = 218.93,
p,0.01]. Duncan’s post-hoc t-tests revealed that the R-Vehicle
and R-Garcinol groups demonstrated increased freezing during
the CS relative to the pre-CS period (p,0.05) that was not
significantly different from one another (p.0.05). We observed no
increase in freezing between the ‘pre-CS’ and ‘reactivation’ period
in the NR-Garcinol group (p.0.05). Further, each of the groups
exhibited equivalent levels of memory during the PR-STM test
[F(2,23) = 0.45; Figure 8d], indicating, as we have observed
previously, that garcinol has no effect on the retention of a fear
memory shortly after injection. During the PR-LTM test,
however, the group injected with garcinol following memory
reactivation (R-Garcinol) exhibited impaired PR-LTM relative to
the other groups [F(2,23) = 63.32, p,0.01; Figure 8d]. Duncan’s
post-hoc t-tests showed that the R-Garcinol group exhibited
statistically lower levels of freezing relative to both the R-Vehicle
and NR-Garcinol groups (p,0.01), which were not found to differ
from one another (p.0.05).
Discussion
While the study of the cellular and molecular mechanisms
underlying the consolidation and reconsolidation of traumatic fear
memories has attracted considerable experimental interest [5–10],
few compounds have to date emerged that are readily useful in a
clinical setting. Recent studies, however, have suggested that the
targeting of ‘epigenetic’ processes, including modifications in
chromatin structure and function, may hold considerable promise
in the treatment of neuropsychiatric diseases that affect memory
and cognition [49–53]. In this study, we have systematically
investigated the potential efficacy of garcinol, a naturally-occurring
HAT inhibitor derived from the diet, in mitigating the consoli-
dation and reconsolidation of Pavlovian fear memories, a type of
persistent aversive memory that is characteristic of anxiety
disorders such as PTSD [4]. We show that local infusion of
garcinol into the LA, the presumed locus of storage of fear
memories [64], impairs the training and retrieval-related acetyla-
tion of histone H3 in the LA. We further show that intra-LA or
systemic administration of garcinol within a narrow window after
either fear conditioning or fear memory recall, respectively,
significantly impairs the consolidation and reconsolidation of a
Pavlovian fear memory and associated neural plasticity in the LA.
Garcinol is a polyisoprenylated benzophenone compound
extracted from the rind of the fruit of Garcinia indica, also known
as Kokum, a tree native to the tropical coastal regions of Western
India [65,66]. While typically not eaten as a fresh fruit, Kokum
rind is instead frequently dried and used as a seasoning for curries
or processed into a syrup suitable for drinking [66]. The readily
consumable juice made from the rind of the Kokum fruit has been
prevalently used in Ayurvedic medicine to treat a remarkably wide
range of ailments, including inflammation, infection, dermatitis,
and gastrointestinal problems [66]. Empirical studies have further
identified anti-oxidant, anti-obesity, anti-tumor and anti-inflam-
matory actions of garcinol or its derivatives [65–69]. While there
are over a dozen existing patents for the potential efficacy of
garcinol in the treatment of various conditions ranging from
inflammation to obesity to cancer [65], our findings are the first to
suggest that garcinol may also be effective, either alone in
combination with existing pharmacological or behavioral inter-
ventions, in the treatment of neuropsychiatric disorders such as
PTSD. Future experiments will be necessary to evaluate this
possibility.
At the molecular level, garcinol has been shown to be a potent
inhibitor of the HAT activity of CREB-binding protein (CBP),
E1A-associated protein (p300), and the p300/CBP-associated
factor (PCAF) [55,70]. Each of these HATs has been widely
studied in memory formation and synaptic plasticity, most notably
using molecular genetic approaches with a focus on hippocampal-
dependent memory paradigms including object recognition,
spatial memory and contextual fear memory [71–81]. These
studies have complemented existing pharmacological studies that
have implicated HAT and HDAC activity in hippocampal long-
term potentiation (LTP) and hippocampal-dependent memory
[75,82–89]. To date, however, only two studies have implicated
HATs in amygdala-dependent ‘cued’ fear memory formation in a
genetically modified mouse model [49,90] while most have found
no effect [71–74,79,81]. These findings suggest that many of the
existing mouse molecular genetic models may not be optimal to
reveal a role for HATs in amygdala-dependent memory. In
contrast, we have shown in the rat that auditory fear conditioning
is associated with an increase in the acetylation of histone H3, but
not H4, in the LA [58], and that intra-LA infusion of the HDAC
inhibitor TSA enhances both H3 acetylation and the consolidation
of an auditory fear memory; that is, STM is not affected, while
LTM is significantly enhanced [58]. Further, bath application of
TSA to amygdala slices significantly enhances LTP at thalamic
and cortical inputs to the LA [58]. Consistent with these findings,
in the present study we show that intra-LA infusion of the HAT
inhibitor garcinol significantly impairs training-related H3 acety-
lation and the consolidation of an auditory fear memory and
associated neural plasticity in the LA; STM and short-term
enhancements in tone-evoked neural activity in the LA are intact,
while LTM and long-term training-related neural plasticity are
significantly impaired. Collectively, our findings point to an
important role for chromatin modifications in the consolidation of
amygdala-dependent fear memories. Additional experiments will
be required to examine the specific HATs that are targeted by
garcinol after fear conditioning and the mechanisms by which they
promote fear memory consolidation and long-term alterations in
synaptic plasticity in the LA.
This is the first study, of which we are aware, to systematically
examine the role of a pharmacological inhibitor of HAT activity
in memory reconsolidation processes. We show that intra-LA
infusion of garcinol following auditory fear memory retrieval
impairs retrieval-related histone H3 acetylation in the LA and
significantly interferes with the reconsolidation of a fear memory
and that of memory-related neural plasticity in the LA; that is,
PR-STM and associated neural plasticity are unaffected, while
PR-LTM is impaired together with a loss of memory-related
plasticity in the LA. We further show that the effect of garcinol
on memory reconsolidation and memory-associated plasticity in
the LA is specific to a reactivated memory and temporally
restricted; we observed no effect of garcinol in the absence of
memory reactivation or following a delayed infusion, findings
which rule out the possibility that garcinol, at the doses chosen
here, may have damaged the amygdala or produced other non-
specific effects that may have affected the reconsolidation
process. Importantly, post-retrieval treatment with garcinol was
observed to effectively impair the reconsolidation of both a
recently formed (within 24 hrs) and a ‘well-consolidated’ (2 week
old) fear memory, suggesting that even older fear memories are
susceptible to reconsolidation impairment using this compound.
This latter finding adds to a growing body of evidence that
amygdala-dependent memories are susceptible to reconsolidation
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interference regardless of their age [19,25,33], and has important
implications for the use of reconsolidation-based approaches in a
clinical setting. Finally, and perhaps most importantly, we show
that fear memories that fail to reconsolidate following post-
retrieval treatment with garcinol are lost in an enduring manner;
they are not subject to spontaneous recovery, to reinstatement
following a series of unsignaled footshocks, or to a shift in the
testing context, all trademark characteristics of fear memories
that are lost due to fear extinction or exposure-based procedures
[91-93]. This latter finding is particularly important not only in a
clinical context, but it also rules out the possibility that garcinol
may have influenced fear memory reconsolidation processes by
promoting facilitated extinction after the reactivation trial.
Indeed, a recent report has suggested that infusion of a p300-
specific HAT inhibitor into the prefrontal cortex can paradox-
ically enhance fear extinction [94]. Our findings, in contrast,
suggest that fear extinction has not been enhanced by garcinol;
rather, local infusion of garcinol into the LA appears to have
specifically interfered with fear memory reconsolidation.
In summary, our findings provide strong evidence that a
naturally-occurring HAT inhibitor derived from the diet can
significantly impair either newly formed or reactivated fear
memories in a widely studied animal model of PTSD. Our
findings suggest that garcinol and other yet to be identified
compounds that target the regulation of chromatin function or
structure may hold great promise as therapeutic agents in
alleviating fear and anxiety disorders characterized by persistent,
unwanted memories when administered either shortly after
traumatic memory formation or in conjunction with ‘reconsoli-
dation’ based forms of psychotherapy.
Materials and Methods
Subjects
Adult-male Sprague-Dawley rats (Harlan), weighing 300–350 g
and aged 2–3 months, were housed individually in plastic cages
and maintained on a 12:12 hr light/dark cycle with food and
water provided ad libitum.
Surgery
Rats were anesthetized with i.p. administration of Ketamine
(100 mg/kg) and Xylazine (6.0 mg/kg) and implanted with 26-
gauge stainless-steel guide cannulas (Plastics One, Roanoke, VA)
in the LA (23.2 mm, 65.2 mm, 28.0 mm relative to Bregma).
Guide cannulas were secured to screws in the skull using a mixture
of dental acrylic and cement and 31-gauge dummy cannulas were
inserted into the guide to prevent obstruction. Buprenex (0.2 mg/
kg) was administered as an analgesic and rats were provided with
at least five days post-operative recovery time. All surgical
procedures were conducted under the guidelines provided in the
National Institutes of Health Guide for the Care and Use of Experimental
Rats and were approved by the Yale University Institutional
Animal Care and Use Committee.
Electrode implantation procedures
Rats were anesthetized under the same procedures as those used
for cannula implantation. Rats were implanted in the left LA with
a tungsten recording electrode (0.1 mm diameter, 1 MV) adhered
to a 26-gauge guide cannula (AP: 23.2 mm; ML: 65.2; DV:
27.4). The recording wire extended 0.75 mm beyond the base of
the guide. A 26-gauge guide cannula was implanted in the right-
LA. A low-impedance copper wire was connected to a stainless
steel bone screw drilled into the skull contralateral to the side of
the recording electrode ,1 mm posterior to Bregma to serve as
the reference for recording purposes. Another stainless steel screw
attached to a copper wire was drilled into the skull ,3 mm
posterior to lambda and served as the ground electrode. Dental
cement was used to anchor the electrodes and connecting device to
the skull. Rats were given at least 5 days to recover from the
surgery before experiments.
Drugs
The PCAF/p300 HAT inhibitor garcinol (Enzo; BML-GR343)
was dissolved in 100% DMSO to a 2 mg/ml stock solution and
then diluted 1:1 in ACSF to a final concentration of 1 mg/ml prior
to infusion into the brain. The vehicle solution for intra-cranial
infusion experiments consisted of 50% DMSO. For systemic
experiments, garcinol was dissolved in 100% DMSO to a stock
solution of 10 mg/mL and administered i.p. at a 10 mg/kg dose.
Vehicle solution for systemic experiments consisted of 100%
DMSO.
Pharmacology and Western blotting experiments
We have recently shown that auditory Pavlovian fear condi-
tioning, but not exposure to tone or shocks alone, leads to an
increase in the acetylation of histone H3 in the LA that is most
prominent at 90 mins after fear conditioning [58]. In a related
study, we showed that auditory fear memory retrieval, but not
exposure to tone alone or to the context in the absence of fear
memory reactivation, leads to a similar increase in histone H3
acetylation at 90 mins [59]. To examine the effect of garcinol on
fear conditioning-related histone acetylation in the LA, cannulated
rats were habituated to handling and the conditioning chambers
(30 min/day/chamber) for four days prior to auditory fear
conditioning consisting of three tone-shock pairings (30 sec,
5 kHz, 75 dB; 1.0 mA). The conditioning chamber (Chamber A)
was a lit chamber with a grid floor. One-hr after tone-shock
pairings rats were infused with either vehicle (0.5 ml/side) or
garcinol (500 ng/side; 0.5 ml). Thirty-min later (90 min following
training) rats were given an overdose of chloral hydrate (600 mg/
kg; i.p.) and brains were removed and frozen at 280uC. An
additional group of naive rats was handled and habituated but not
exposed to the training chamber prior to infusion of 50% DMSO
vehicle (0.5 ml/side) and was sacrificed 30 min following infusions.
To examine the effect of garcinol on fear memory retrieval-related
histone acetylation in the LA, rats were habituated to both the
conditioning (Chamber A) and testing chambers for four days. The
testing chamber (Chamber B) consisted of a dark chamber with a
black plastic floor which was washed immediately before the
reactivation session with a distinctive peppermint soap. On the
fifth day, rats were given three tone-shock pairings in Chamber A.
The next day, rats were given an auditory fear memory
reactivation session consisting of a single presentation of a
30 sec, 5 kHz, 75 dB tone administered in Chamber B. One
hour later, rats were given intra-LA infusions of either vehicle
(0.5 ml/side) or garcinol (500 ng/side; 0.5 ml). Thirty min later
(90 min after the reactivation session) all rats were given an
overdose of chloral hydrate (600 mg/kg; i.p.), and brains were
removed and frozen at 280uC.
Punches containing the LA around the cannula tips were
obtained with a 1 mm punch tool (Fine Science Tools, Foster
City, CA) from 400-mm-thick sections taken on a sliding freezing
microtome. Punches were manually dounced in 100 ml of ice-
cold hypotonic lysis buffer [10 mM Tris-HCl, pH 7.5, 1 mM
EDTA, 2.5 mM sodium pyrophosphate, 1 mM phenylmethyl-
sulfonyl fluoride, 1 mM b-glycerophosphate, 1% Igepal CA-630,
1% protease inhibitor cocktail (Sigma) and 1 mM sodium
orthovanadate]. Sample buffer was immediately added to the
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homogenates, and the samples were boiled for 4 min. Homog-
enates were electrophoresed on 18% Tris-HCl gels and blotted
to Immobilon-P (Millipore, Bedford, MA). Western blots were
then blocked in TTBS buffer (50 mM Tris-HCl, pH 7.5,
150 mM NaCl, and 0.05% Tween-20) with 5% dry milk and
then incubated with the appropriate primary antibody [AcH3
(pan), 1:3,000, Millipore; total H3, 1:5,000, Millipore]. Blots
were then incubated with anti-rabbit antibody conjugated to
horseradish peroxidase (Cell Signaling, Danvers, MA) and
developed using West Dura chemiluminescent substrate (Pierce
Laboratories, Rockford, IL). Western blots were developed in the
linear range used for densitometry. Densitometry was conducted
using Image J software. To control for inconsistencies in loading,
optical densities for total H3 protein were first normalized to
GAPDH protein (1:20,000; Abcam). Acetylated H3 protein was
then normalized to total H3 protein. For analysis, all data were
normalized to the average value of naı¨ve controls and analyzed
using ANOVA.
Behavioral experiments
Rats were handled for two days prior to conditioning. On the
second handling day, dummy cannulas were removed to check for
patency. Rats were then habituated to Chamber A for 15 minutes
(Day 1). The following day (Day 2), rats were placed in Chamber
A and presented with three tone-shock pairings consisting of a
30 sec, 5 kHz, 75 dB tone that co-terminated with a 1 sec, 1.0 mA
foot shock. One hour later, rats received intra-LA infusion of
either vehicle (0.5 ml/side) or garcinol (500 ng/side; 0.5 ml).
Infusions were made over 4 min and the infusion cannulas were
left in place for at least 2 min following infusion to facilitate
diffusion throughout the LA. Three hr after infusions, rats were
tested for short-term memory (STM) consisting of the presentation
of three CS tones (30 sec, 5 kHz, 75 dB) in Context B. Twenty-
one hr later (Day 3), all rats received a long-term memory (LTM)
test consisting of 10 tone CS presentations (30 sec, 5 kHz, 75 dB)
in context B.
For the reconsolidation experiments, rats were habituated and
conditioned as before. The next day (Day 3), rats were placed in
Chamber B and received either a single tone CS presentation, to
serve as a memory reactivation trial, or no tone presentation, to
serve as a ‘no reactivation’ trial. One hour later, rats received
intra-LA infusion of either vehicle (0.5 ml/side) or garcinol
(500 ng/side; 0.5 ml). Three hr after infusions, rats were tested
for post-reactivation short-term memory (PR-STM) consisting of
the presentation of three CS tones (30 sec, 5 kHz, 75 dB) in
Context B. Twenty-one hr later (Day 3), all rats received a post-
reactivation long-term memory (PR-LTM) test, which consisted of
10 tone CS presentations (30 sec, 5 kHz, 75 dB) in context B. Rats
used to examine the effect of HAT inhibition on the reconsolida-
tion of a ‘‘well-consolidated’’ memory were tested under identical
parameters, however they were returned to their homecage for
two weeks following conditioning prior to the reactivation session.
An additional behavioral experiment examined whether the
reconsolidation deficit induced by HAT inhibition in the LA was
sensitive to spontaneous recovery, reinstatement, or to a shift in
the testing context. The protocol for this experiment was adapted
from that of a previous study by Duvarci and Nader [60]. Rats in
this experiment were trained in Chamber A, reactivated 24 hrs
later in Chamber B and given intra-LA infusion of vehicle or
garcinol as described above. Three and 21 hr after infusion, rats
were returned to Chamber B and tested for PR-STM and PR-
LTM, respectively. One week after the initial PR-LTM test rats
were returned to Chamber B and tested for spontaneous recovery
with five tone CS presentations. The next day, they were placed in
a novel context (Chamber C), scented with cedar and brightly
illuminated, and given a reinstatement session consisting of three
unsignaled footshocks (1 sec, 1.0 mA). Twenty-four hours later, all
rats were returned to Chamber B and tested for reinstatement of
fear with five tone CS presentations. The next day, rats were
introduced to a final novel context (Chamber D), consisting of a lit
behavior box with a floral scented cotton-padded floor, and tested
with three tone CS presentations to examine the context generality
of the reconsolidation deficit.
Behavioral experiments employing systemic garcinol injections
were conducted using non-cannulated rats, and, accordingly, a
slightly weaker fear conditioning paradigm was used consisting of
2 tone-shock pairings (1 sec, 0.5 mA). Thirty-min after condition-
ing, rats received i.p. injection of either vehicle or garcinol
(10 mg/kg). Here, we used a 30 min post-training injection time
point (rather than 1 hr as in our intra-LA experiments) to allow
additional time for the drug to enter the system. STM and LTM
were examined at 3 and 21 hr following injections in Chamber B.
Examination of the effect of systemic garcinol administration on
fear memory reconsolidation was conducted under the aforemen-
tioned parameters, however twenty-four hr after training rats were
given either a tone-reactivation or no-reactivation session followed
by i.p. injections 30 min later and subsequent PR-STM and PR-
LTM tests.
Each behavioral test was videotaped for subsequent scoring and
scored by an observer who was blind to the experimental
conditions. Freezing was defined as a lack of movement, excluding
that necessary for respiration, and was quantified as a percentage
of the amount of time the rat spent engaged in freezing behavior
during the CS presentations. All data were analyzed with ANOVA
and Duncan’s post-hoc t-tests. Repeated measures ANOVAs were
used for multiple trial comparisons. Differences were considered
significant if p,0.05. Only data from those rats with bilaterally
well-placed cannulas within the borders of the LA were included in
the analyses.
Neurophysiological recordings
Awake-behaving neurophysiology took place in a custom-made
electromagnetic shielded recording chamber designed for delivery
of auditory stimuli and recording. The chamber was kept within
a ventilated and temperature-regulated acoustic isolation room.
Stimulus delivery and data acquisition were controlled by
SciWorks Experimenter Real-time 7.0 (DataWave). During
recording, rats were exposed to a modified CS consisting of a
series of tone ‘pips’ (20 presentations of a 50 ms, 75 dB, 1 kHz
tone pips, delivered at a frequency of 1 Hz) from a speaker
mounted on the ceiling of the recording chamber. The tone pips
were triggered by TTL signals generated by SciWorks. The TTL
signals were converted (Coulbourn, H91-24, 5 V TTL to 24 V
converter) and sent to a tone generator (Coulbourn, H12-07,
Seven-Tone Audio Cue). During recordings, the implanted
electrodes were connected to a Micro-Miniature Headstage
(DataWave). Neural signals were picked up (Legacy PCI data
acquisition bundles, Model: DT3010), amplified (16-channel A-
M Systems microelectrode amplifier, Model: AM-3600) and
saved for off-line analysis.
On day 1 of each experiment, rats were handled and habituated
to the recording chamber and cable connection for 15 min each.
On days 2 and 3, baseline auditory-evoked field potentials (AEFPs)
elicited by 3 presentations of the 20 tone-pip CS series were
recorded (ITI = 2 mins) from the LA, for a total of 60 tone pip
presentations. On day 4, rats received 3 tone-pip shock pairings in
an illuminated chamber consisting of a series of 20-tone-pip
presentations which co-terminated with a 1s, 1.0mA footshock
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administered through the grid-floor. One-hr following training rats
received intra-LA infusion of either vehicle (0.5 ml/side) or
garcinol (500 ng/side; 0.5 ml). Three-hrs later rats were placed
into a modified chamber which included a flat black peppermint
scented floor for STM testing and AEFP recordings consisting of 3
presentations of the tone-pip CS series were recorded (ITI
= 2 mins), for a total of 60 tone pip presentations (identical to
baseline recordings). The following day rats were placed back in
the modified chamber and examined for LTM with 9 tone-pip
presentations.
For the reconsolidation experiments, rats underwent habitua-
tion, baseline recording sessions, and fear conditioning as in the
consolidation experiment. The next day (Day 5), rats were placed
in the modified chamber (black peppermint scented floor) and
received either a single tone-pip series presentation, to serve as a
memory reactivation trial, or no tone-pip presentation, to serve as
a ‘no-reactivation’ trial. One-hour later rats were infused with
either vehicle (0.5 ml/side) or garcinol (500 ng/side; 0.5 ml).
Three-hrs after infusions, rats were tested for PR-STM and
AEFPs with 3 presentations of the tone-pip CS series, in the
modified chamber. Twenty-one hr later (Day 6) rats were tested
for PR-LTM and AEFPs with 9 presentations of the tone-pip CS
series.
Rats’ freezing behavior was recording during all sessions for
off-line scoring. Following the completion of testing all rats were
rapidly and deeply anesthetized prior to transcardial-perfusions
and brain extractions for electrode placement analyses. For data
analysis during STM/PR-STM sessions, all 60 AEFPs were
averaged into a single waveform. Data analysis for the LTM/
PR-LTM sessions was conducted based on the average waveform
from the last 60 AEFPs. Spike2 software (Cambridge Electronics
Design, Cambridge, UK) was used to analyze the amplitude of
the short-latency negative-going component of the AEFP from
the initial point of deflection to its maximal negativity, which
occurs ,12–16 ms from the onset of the pip [62–64]. The
amplitude of AEFPs recorded during the STM and LTM tests
were expressed as a percentage of the baseline amplitude for
comparison between vehicle and garcinol-treated groups. Data
were analyzed using t-tests and differences were only considered
significant is p,0.05.
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